Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study

NCT06439576 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT06439576
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06439576 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
China Faricimab Real World Evidence: Evaluation of Faricimab Effectiveness, Safety and Treatment Pattern, in Diabetic Macular Edema, Retinal Vein Occlusion and Neovascular Age-Related Macular Degeneration: The Farseeing Study
Lead sponsor
Hoffmann-La Roche
Phase
Observational
Overall status
Active, not recruiting
Start date
May 9, 2024
Completion date
November 15, 2027
Enrollment
1,000 (estimated)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema, neovascular age-related macular degeneration, retinal vein occlusion